Sunshine Average Receivables from 2010 to 2025

SBFMW Stock  USD 0.20  0.01  4.76%   
Sunshine Biopharma Average Receivables yearly trend continues to be fairly stable with very little volatility. Average Receivables is likely to outpace its year average in 2025. During the period from 2010 to 2025, Sunshine Biopharma Average Receivables regression line of quarterly data had mean square error of 119.2 B and geometric mean of  66,955. View All Fundamentals
 
Average Receivables  
First Reported
2010-12-31
Previous Quarter
M
Current Value
2.1 M
Quarterly Volatility
808.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Average Receivables Growth Pattern

Below is the plot of the Average Receivables of Sunshine Biopharma Warrant over the last few years. It is Sunshine Biopharma's Average Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
Average Receivables10 Years Trend
Slightly volatile
   Average Receivables   
       Timeline  

Sunshine Average Receivables Regression Statistics

Arithmetic Mean757,595
Geometric Mean66,955
Coefficient Of Variation106.77
Mean Deviation661,534
Median959,976
Standard Deviation808,919
Sample Variance654.3B
Range2.2M
R-Value0.91
Mean Square Error119.2B
R-Squared0.83
Slope154,788
Total Sum of Squares9.8T

Sunshine Average Receivables History

20252.1 M
2024M
20232.2 M
2017960 K

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Average Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Average ReceivablesM2.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.